7DW8-5 Glycolipid


7DW8-5 is a glycolipid analog related to Alpha-Galcer which is an immunostimulate iNKT agonist upregulating cytokine production in human and mice. While majority of research with 7DW8-5 as a vaccine adjuvant the upregulated expression of cytokines may have cytoxic effects on tumors, infectious diseases and autoimmune disorders.

7DW8-5 chemical structure of 7DW8-5 is similar to Alpha-GalCer with the only difference with a shorter fatty acyl chain and florinated benzyme ring at end of fatty acyl chain.


7DW8-5 chemical structure
7DW8-5 structure


7DW8-5 chemical name:

7DW8-5 molecular formula: C41H72FNO9

7DW8-5 ppearance: White to off-white powder

Solubility: 7DW8-5 is insoluble in water, methanol or ethanol. 7DW8-5 is soluble in dimethyl sulfoxide (DMSO). The solution in phosphate buffered saline (PBS) with 10% Tween 20 or 80 remained clear at 4°C for 7 days. The solution in PBS with 5% Tween 80 remained clear at 4°C for 5 days. After more than 20 days at 4°C the samples became gel-like substance except the solution in PBS with 10% Tween 80 which remained clear solution with some floats.

7DW8-5 References:

1. Design of a Potent CD1d-binding NKT Cell Ligand as a Vaccine Adjuvant.

2. Clinical Development of a Novel CD1d-binding NKT Cell Ligand as a Vaccine Adjuvant.

Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.

A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates

Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.

A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice

Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells

Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect


New 7DW8-5 glycolipid


Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch


Meet Funakoshi Company
at the following meetings:

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

NIH Festival
Bethesda, Maryland
September 14-15, 2017

Philadelphia, PA
December 2-6, 2017